TICKERNERD
Menu
PYXSPYXSHealthcare · Biotechnology

PYXS Stock Forecast: Pyxis Oncology, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$3.08
−1.28% on the day

The 10 Wall Street analysts covering Pyxis Oncology, Inc. hold a median 12-month price target of $7 — +127.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$256.9M
Ticker Nerd rank
80 / 100
Median analyst target
$7.00
Analysts covering
10
Total return, dividends reinvested
1W
+2.3%
1M
+38.1%
YTD
+167.8%
1Y
+133.3%
From 52W high
−42.3%
From 52W low
+190.6%
$1.06
$5.34
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PYXS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pyxis Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
88
Momentum
81
Growth
80
Issuance
67
Value
67
Size
65
Revisions
50
Quality
35
Volatility
25

Accruals (88): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (25): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PYXS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PYXS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26PYXSHigh $12.00Median $7.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
9 Buy1 Hold0 Sell
Low $5.00Median $7.00High $12.00

The green dot is the last close — the median target sits +127.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Aug 2026HC Wainwright & Co.ReiteratesBuy$7.00
3 Aug 2026Wells FargoInitiatesOverweight$12
3 Aug 2026Wells FargoInitiatesOverweight—
2 July 2026Leerink PartnersMaintainsOutperform$9.00 → $7.00
2 July 2026Leerink PartnersMaintainsOutperform—
5 May 2026WedbushInitiatesOutperform—
24 Mar 2026HC Wainwright & Co.ReiteratesBuy—
24 Mar 2026StifelMaintainsBuy—
19 Dec 2025HC Wainwright & Co.MaintainsBuy—
19 Dec 2025RBC CapitalMaintainsOutperform—
24 Nov 2025Stephens & Co.MaintainsOverweight—
4 Nov 2025GuggenheimMaintainsBuy—
4 Sept 2025GuggenheimInitiatesBuy—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
19 May 2025HC Wainwright & Co.ReiteratesBuy—
19 Mar 2025HC Wainwright & Co.ReiteratesBuy—
19 Mar 2025RBC CapitalReiteratesOutperform—
20 Dec 2024HC Wainwright & Co.ReiteratesBuy—
20 Dec 2024RBC CapitalReiteratesOutperform—
21 Nov 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PYXS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PYXS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Pyxis Oncology, Inc. (PYXS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.4×

Cheaper than 86% of US stocks

Price / sales
23.3×

Cheaper than 9% of US stocks

Price / book
6.2×

Cheaper than 17% of US stocks

EV / EBITDA
−2.8×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−812.7%

Higher than 6% of US stocks

Net margin
82.8%

Higher than 98% of US stocks

Returns & dividend
Return on equity
−179.1%

Higher than 8% of US stocks

Return on assets
−63.0%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PYXS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PYXSPyxis Oncology, Inc.$256.9M
80
ALECAlector, Inc.$257.6M
42
SLGLSol-Gel Technologies Ltd.$254.1M
45
NAGENiagen Bioscience, Inc.$254.0M
54
MGNXMacroGenics, Inc.$260.6M
67
CGENCompugen Ltd.$247.3M
82
LCTXLineage Cell Therapeutics, Inc.$269.0M
56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pyxis Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PYXS news & analysis

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

GlobeNewsWire · 13 Aug 2026positive

Pyxis Oncology reported financial results for the quarter ended June 30, 2026, and said updated clinical data from its MICVO program remain on track for 2026. The company also closed a private placement financing of up to $114 million, with about $50 million in upfront gross proceeds, extending its cash runway into the second quarter of 2027.

Why it matters — PYXS watchers would care because the financing extends the company's cash runway into the second quarter of 2027 while key MICVO clinical data updates are expected later this year.

FAQ

Frequently asked questions about PYXS stock

What is the PYXS stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Pyxis Oncology, Inc. have a median 12-month price target of $7, with estimates ranging from $5 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PYXS stock a buy right now?

Of the 10 analysts covering Pyxis Oncology, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pyxis Oncology, Inc. 80 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PYXS?

As at 22 Aug 2026, Pyxis Oncology, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (88 of 100).

Will PYXS stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +127.3% from the last close, and Ticker Nerd's factor model ranks Pyxis Oncology, Inc. 80 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PYXS stock forecast for 2030?

No analyst covering Pyxis Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PYXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $12 over the next 12 months.

How has PYXS stock performed over the past year?

Pyxis Oncology, Inc. returned +133.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pyxis Oncology, Inc. do?

Pyxis Oncology Inc. is a biopharmaceutical company dedicated to developing an innovative portfolio of next-generation medicines targeting cancer.

What is the latest news on PYXS?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones". Pyxis Oncology reported financial results for the quarter ended June 30, 2026, and said updated clinical data from its MICVO program remain on track for 2026. The company also closed a private placement financing of up to $114 million, with about $50 million in upfront gross proceeds, extending its cash runway into the second quarter of 2027.

Company

About Pyxis Oncology, Inc.

Pyxis Oncology Inc. is a biopharmaceutical company dedicated to developing an innovative portfolio of next-generation medicines targeting cancer. The primary focus of the company lies in harnessing proprietary technologies to advance novel antibody-based therapeutics. By emphasizing precision medicine, Pyxis Oncology aims to create therapies that improve the standard of care for cancer patients, addressing specific unmet medical needs. The company operates in the highly specialized pharmaceutical and biotechnology sectors, where breakthrough treatments can significantly impact patient outcomes. Its ongoing research and development efforts place Pyxis Oncology among the trailblazers in the medical industry, contributing to the expansion of targeted therapy options. With its dedication to pioneering drug discovery, Pyxis Oncology plays a crucial role in the evolving landscape of cancer treatment, which is a critical component of the broader healthcare and life sciences markets. The company's mission to transform the oncology therapeutic field underscores its importance in the pursuit of comprehensive cancer care solutions.

CEO Mr. Thomas Civik · 56 employees · United States · https://www.pyxisoncology.com